Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 6/20 | 0.35 |
| ▸ | SSTR2 | P30874 | 6/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 6/20 | 0.35 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | GJB2 | P29033 | 4/20 | 0.32 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.31 |
| ▸ | CDC25B | P30305 | 3/20 | 0.31 |
| ▸ | FGF1 | P05230 | 1/20 | 0.30 |
| ▸ | FGF2 | P09038 | 1/20 | 0.30 |
| ▸ | VEGFA | P15692 | 1/20 | 0.30 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9780103 | 0.83 | SSTR1 (0.49) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL14632200 | 0.83 | SSTR1 (0.49) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL14086731 | 0.81 | GJB2 (0.43) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| B-D-Galactose SCHEMBL29368537 | 0.80 | LGALS8 (0.38) | CD209 | |
| B-D-Galactose SCHEMBL28286620 | 0.80 | LGALS8 (0.38) | CD209 | |
| SCHEMBL7538441 | 0.77 | SSTR1 (0.47) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL804961 | 0.76 | CD209 (0.40) | GJB2CD209FGF1FGF2VEGFA | |
| SCHEMBL14303177 | 0.75 | GJB2 (0.43) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| B-D-Galactose SCHEMBL28293949 | 0.75 | IGF2R (0.40) | CD209PTPN1CDC25B | |
| SCHEMBL12798586 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338257-A1 | ANHYDROUS CONCENTRATED HAIR CARE COMPOSITIONS IN THE FORM OF A PASTE | EVERIST INC. (CA) | 2023-10-26 | — | — | US | disclosed |
| WO-2022094731-A1 | ANHYDROUS CONCENTRATED HAIR CARE COMPOSITIONS IN THE FORM OF A PASTE | EVERIST INC. (CA) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338257-A1 | ANHYDROUS CONCENTRATED HAIR CARE COMPOSITIONS IN THE FORM OF A PASTE | SUCLG1, CUTA, OTC | SSTR1 1656/4885SSTR2 2710/4885SSTR4 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.